Antibe Therapeutics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATE.TO research report →
Companywww.antibethera.com
Antibe Therapeutics Inc. , a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs.
- CEO
- Daniel Marcel Legault
- IPO
- 2013
- Employees
- 11
- HQ
- Toronto, ON, CA
Price Chart
Valuation
- Market Cap
- $15.64M
- P/E
- -0.79
- P/S
- 0.00
- P/B
- 0.38
- EV/EBITDA
- -0.46
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -40.16%
- ROIC
- -28.48%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-19,475,000 · 22.27%
- EPS
- $-0.37 · 24.49%
- Op Income
- $-20,546,000
- FCF YoY
- 3.63%
Performance & Tape
- 52W High
- $1.23
- 52W Low
- $0.15
- 50D MA
- $0.70
- 200D MA
- $0.66
- Beta
- 0.19
- Avg Volume
- 139.88K
Get TickerSpark's AI analysis on ATE.TO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ATE.TO Coverage
We haven't published any research on ATE.TO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ATE.TO Report →